Abstract
Two separate systematic reviews and meta-analyses published in this edition of the American Journal of Gastroenterology conclude that proton pump inhibitor (PPI) use is associated with an ~70% increase in the risk of Clostridium difficile infection (CDI). The two reviews employed different methodology but reached very similar conclusions. However, since the quality of evidence from the individual studies that were included in these analyses is relatively weak, their conclusions must be interpreted cautiously. Observational studies--and even well-conducted systematic reviews of observational studies--rarely provide adequate evidence to prove causality rather than mere association. However, given both the widespread use of PPIs and the increasing incidence and importance of CDI, it is important that this association is adequately explored.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
